In lupus-susceptible mice, PKCβ deficiency abolished nephritis and autoantibody formation by inducing an anergic B-cell phenotype and treatment with the PKCβ-specific inhibitor enzastaurin prevented the development of lupus (Oleksyn et al. 2013). Here, PRKCB is linked to systemic lupus erythematosus.